Dr. Jeffrey Irving Menashe - NPI #1871596551

Hematologist & Oncologist located in Portland, OR

Oregon Portland Hematology & Oncology Dr. Jeffrey Irving Menashe Information


Dr. Jeffrey Irving Menashe is a male Hematologist & Oncologist (taxonomy code 207RH0003X) located in Portland, Oregon. Dr. Jeffrey Irving Menashe's NPI Number is #1871596551 and has been listed in the NPI registry for 11 years. Dr. Jeffrey Irving Menashe's practice location is listed as: 5050 Ne Hoyt St Ste 256 Portland, OR 97213-2982 and can be reached via phone at (503) 239-7767.

Hematology & Oncology Taxonomy

The taxonomy code for Dr. Jeffrey Irving Menashe's main specialty, Hematology & Oncology, is 207RH0003X. An internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered.



Be the first to rate Dr. Menashe

Thanks for sharing your opinion!

‡ Descriptions, provider messages, and reviews are user submitted. While we make our best effort to verify the accuracy of information submissions, DocBios cannot guarantee that the information is accurate and/or up to date. Please verify any and/or all information with the provider. DocBios is not an advice or referral service and does not guarantee, approve, or endorse any particular healthcare provider.

Health Care Provider Information
 NPI # 1871596551
 Phone (503) 239-7767
 Fax (503) 215-6897
5050 Ne Hoyt St
Ste 256
Portland, OR 97213-2982
 Gender M
 Website Not provided
  • Hematology & Oncology (OR)
Business Information
  • Sole Proprietor? No
  • Is Sub-Organization? Not Available
  • Parent Org Name: Not Available
 Updated 12/22/2011
 Added 5/24/2005
 Viewed on 10/25/2016
Health Care Providers Nearby

Thanks! Your edit was sucessfully submitted. Changes will be displayed after DocBios.com editors have reviewed your submission.